PMN
ProMIS Neurosciences

816
Loading...
Loading...
News
all
press releases
Leede Jones Gab Weighs in on ProMIS Neurosciences, Inc.'s FY2024 Earnings (NASDAQ:PMN)
ProMIS Neurosciences, Inc. (NASDAQ:PMN - Free Report) - Leede Jones Gab cut their FY2024 EPS estimates for ProMIS Neurosciences in a research note issued to investors on Wednesday, April 3rd...
Zolmax·1y ago
News Placeholder
More News
News Placeholder
ProMIS Neurosciences, Inc. Expected to Earn FY2028 Earnings of $0.62 Per Share (NASDAQ:PMN)
ProMIS Neurosciences, Inc. (NASDAQ:PMN - Free Report) - Equities research analysts at Leede Jones Gab issued their FY2028 earnings per share (EPS) estimates for ProMIS Neurosciences in a research...
Ticker Report·1y ago
News Placeholder
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
Globe Newswire·1y ago
News Placeholder
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE...
Globe Newswire·2y ago
News Placeholder
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
Adds Key U.S. and International Patent Allowances to Further Protect the Company's Monoclonal Antibody Therapeutic for the Treatment of Alzheimer's DiseaseCAMBRIDGE, Massachusetts and TORONTO...
Globe Newswire·2y ago
News Placeholder
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
Globe Newswire·2y ago
News Placeholder
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson's disease and Dementia with Lewy bodiesCAMBRIDGE, Massachusetts and TORONTO...
Globe Newswire·2y ago
News Placeholder
ProMIS Neurosciences Issues Letter to Shareholders
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...
Globe Newswire·2y ago
News Placeholder
ProMIS Neurosciences, Inc. Announces Leadership Transition
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive OfficerCAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences...
Globe Newswire·2y ago

Latest PMN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.